Products | KII Ultracentrifuge | Alfa Wassermann Separation Technologies

By: Alfa Wassermann Separation Technologies  09-12-2011
Keywords: Vaccine, Ultracentrifuge

Alfa Wassermann's over 40 years of experience in manufacturing and supporting continuous flow Ultracentrifuges in the vaccine manufacturing industry culminates in the KII Ultracentrifuge. The KII’s control system has all the features expected from modern bioprocess equipment. The large rotor volumes allow for high process volume for manufacturing vaccines and other bio-products.

Highly regarded for its versatility, reliability and ease of operation, the KII is considered the benchmark for quality in the large scale commercial preparation and production of viruses for vaccine and immunotherapy products.

The high speeds and capacity of the KII together with its separating efficiency, reliability and ease of operation has made this instrument the accepted device among major pharmaceutical companies for production of purified vaccines.  The high resolution obtained with the KII and PKII is now producing vaccine 10 times purer than was previously possible.

Specification
Throughput: 60  l/h
Rotor capacity: up to 8 liters
Speed: 40 500 rpm
Centrifugal force: 121 200 xg
Rotor temperature monitoring
Automatic and Manual Control

The KII features:

  • Up to 8.0 L rotor capacity and 200 L process volume
  • Unattended operation
  • Batch, Alarm and Event logs
  • User password access for operations with an auto logout facility
  • BL2+ environment compatible
  • Closed loop seal cooling contains any aerosols generated
  • Clean room class C/D compatible
  • Complete validation support
  • Conformity to: CE, 21CFR Part 11, GAMP

 The benefits of continuous flow ultracentrifugation are:

  • No buffer exchange diafiltration needed
  • No pre-concentration of harvest material required
  • Pre-clarification option with the K6 rotor
  • Single step concentration and purification
  • Retains the infectivity of viruses in the low shear gradient environment
  • Greater than 80% product yields

The KII Ultracentrifuge has a range of rotor assemblies to choose from to suit vaccine and viral vector purification and manufacturing.

Air Drive, Electrical Drive technology

Drive technologies are available as electric motor or air drive.  The air drive developed in the 1960s and used commercially since 1967 provides a truly proportional control of speed and acceleration for reliability and long life operation.

The ‘e-drive’ combines the industry standard ultracentrifugation technology of the Alfa Wassermann KII with the up to date electric drive technology, to create an Ultracentrifuge which is reliable, compact and low cost to run for Bio-pharmaceutical R&D and for cGMP manufacturing.

Keywords: Ultracentrifuge, Vaccine,

Contact Alfa Wassermann Separation Technologies

Email

Print this page

Other products and services from Alfa Wassermann Separation Technologies

09-12-2011

Services | Custom Design Services

To meet the needs of pharmaceutical manufacturing and our customers specific design requirements Alfa Wassermann provides a Design Qualification pipeline to generate user specific hardware and software interfaces. No other company can match the history of innovation, the breadth of experience or the commitment to customer service that Alfa Wassermann has dedicated to the biopharmaceutical industry.


09-12-2011

Products | Promatix 1000™ | Alfa Wassermann Separation Technologies

The AWST scalable cores which are available with the Promatix 1000™ enable researchers to translate a lab scale traditional batch-type small scale processes using swing out and angle rotors to a continuous flow method while still only requiring research scale process volumes.